ADVANCED KRAS G12D MUTANT SOLID TUMORS
Clinical trials for ADVANCED KRAS G12D MUTANT SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new ADVANCED KRAS G12D MUTANT SOLID TUMORS trials appear
Sign up with your email to follow new studies for ADVANCED KRAS G12D MUTANT SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail targets tough cancers with KRAS G12D mutation
Disease control OngoingThis study tests a new drug called HRS-4642 combined with other cancer medicines in people with advanced solid tumors that have a specific genetic change (KRAS G12D). The goal is to check safety, find the best dose, and see if the combination shrinks tumors. About 47 adults aged …
Matched conditions: ADVANCED KRAS G12D MUTANT SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated May 18, 2026 12:10 UTC
-
New targeted drug shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new drug, HRS-4642, in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goal is to find a safe dose and check for side effects. About 102 adults with this mutation who have few other options will take …
Matched conditions: ADVANCED KRAS G12D MUTANT SOLID TUMORS
Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated May 18, 2026 12:02 UTC